AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02819375
Drug: Propofol+Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg propofol+0.5 mg/kg remifentanil
Trial: NCT00321412
Drug: AST-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, sachet, 2 grams three times daily for 8 weeks
Trial: NCT02475447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo-matched control
Trial: NCT03910946
Drug: Tuberculin, Purified Protein 5Unt/0.1 mL Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuberculosis (diagnosis)-Tuberculin, purified protein derivative (PPD) is indicated as a diagnostic aid in the detection of Mycobacterium tuberculosis infection. It is also indicated when BCG vaccination or isoniazid prophylaxis is being considered
Trial: NCT00469729
Drug: StemEx®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The stem/progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood cells, which is infused to subject at a rate of 1-3 ml/min in combination with non-manipulated cells derived from the same cord blood unit.
Trial: NCT02777788
Drug: JinFuKang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treated with chemotherapy
Trial: NCT02777788
Drug: XingZaoRuanJian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treated with chemotherapy
Trial: NCT02119000
Drug: PEG/electrolytes 2L/2L split dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol 17gm X 4 At 18h00 the day prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes On the day of the procedure, 4-5 hours prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes
Trial: NCT00985374
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg or 10mg po daily
Trial: NCT00985374
Drug: RG1507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16mg/kg iv every 3 weeks
Trial: NCT03672825
Drug: REcycled CartiLage Auto/Allo IMplantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
Trial: NCT03583346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matched to M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
Trial: NCT00025142
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00025142
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025142
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02716285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule, containing microcrystalline cellulose
Trial: NCT00074191
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01191385
Drug: Any treatment for unresectable HCC as chosen by the physician
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only those patient are allowed to be enrolled that receive any HCC treatment for unresectable HCC as chosen by the physician except sorafenib. During the course of the study, each treatment is allowed.
Trial: NCT01410604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet of 500 mg oral placebo every 12 hours for 3 months.
Trial: NCT00406237
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of tigecycline 50 mg, as a 30-minute infusion
Trial: NCT00753142
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive a glucose infusion consisting of 10% dextrose infused intravenously at a rate of 200 mg/m\^2/min for 20 hours.
Trial: NCT02537925
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200mg bid po, to the end of concurrent radiotherapy
Trial: NCT02205138
Drug: ALLOB® cells with ceramic scaffold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia
Trial: NCT01667614
Drug: spironolacone 25 mg tablets added to losartan
RxNorm normalized name: losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: spironolactone 25 mg once daily added to losartan
Trial: NCT01625182
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules
Trial: NCT02412319
Drug: Anti-HBV placenta transfer factor injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
Trial: NCT00447278
Drug: Other standard therapy for ADHD
RxNorm normalized name: Other drugs for bile therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
Trial: NCT02024009
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given in combination with gemcitabine, known as GemCap.
Trial: NCT01897389
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions
Trial: NCT01897389
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions
Trial: NCT04172272
Drug: Systemic multimodal analgesia administered intravenously
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed.
Trial: NCT02201576
Drug: Plasma exchanges and intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg)~3. oral dexamethasone (20 mg po at day-1, day-3, day-5, day-7 of the two first intravenous immunoglobulins courses)
Trial: NCT02967887
Drug: cisplatin and 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion of Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system (chemoport)
Trial: NCT02022527
Drug: Placebo (for Aspirin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic 75 mg Aspirin
Trial: NCT00731198
Drug: Hyoscine-N-butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine-N-butylbromide 20mg was administered intravenously 15 minutes before ERCP.
Trial: NCT00420836
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03736369
Drug: DWP14012 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 40mg, tablet, orally, once daily for up to 8 weeks
Trial: NCT03736369
Drug: DWP14012 40mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
Trial: NCT02184117
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary or intravenous adenosine to induce hyperemia for reference FFR
Trial: NCT02184117
Drug: Contrast Media
RxNorm normalized name: CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of contrast medium to induce hyperemia for contrast FFR
Trial: NCT00820092
Drug: Xerecept 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 hour infusion
Trial: NCT00820092
Drug: Xerecept 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 hour infusion
Trial: NCT00820092
Drug: Xerecept 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 hour infusion
Trial: NCT01374789
Drug: GemCis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3
Trial: NCT05141994
Drug: 2.5mg of BAT5906
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 2.5mg of BAT5906
Trial: NCT02447029
Drug: vaginal 2% Xylocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block
Trial: NCT02568423
Drug: Placebo - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02568423
Drug: Placebo - SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00694343
Drug: Ringer's Lactate solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mL Ringer's Lactate solution
Trial: NCT01257542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 10 mL dose of matching placebo syrup
Trial: NCT03177850
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Trial: NCT00875667
Drug: Investigators choice single agent
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
Trial: NCT02162433
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to arms 2,4. Serves as the placebo.
Trial: NCT01609192
Drug: Hydrea® (hydroxyurea )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment by hydroxyurea (20-30 mg/kg/day) for 6 months
Trial: NCT01194440
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT01684800
Drug: C: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 orally disintegrating tablet every night during study period
Trial: NCT01145222
Drug: A. CNS 7056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial low dose plus supplemental doses as necessary.
Trial: NCT01145222
Drug: B. CNS 7056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial intermediate dose plus supplemental doses as necessary.
Trial: NCT01145222
Drug: C. CNS 7056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial high dose plus supplemental doses as necessary.
Trial: NCT01674855
Drug: PEG-G-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle
Trial: NCT00668564
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days before Transplant Drug Frequency~* 4 Cyclophosphamide Once, given over 2 hours~* 3 Cyclophosphamide Once, given over 2 hours~* 2 Cyclophosphamide Once, given over 2 hours~* 1 Cyclophosphamide Once, given over 2 hours
Trial: NCT00668564
Drug: Campath-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days before Transplant Drug Frequency~12 Campath-1H Once, given over 2 hours~11 Campath-1H Once, given over 2 hours~10 Campath-1H Once, given over 2 hours
Trial: NCT02911467
Drug: Pyruvate (13C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyruvate injection followed by an MRI scan.
Trial: NCT01625520
Drug: SOM230 alone or in combination with RAD001.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOM230 (pasireotide) 60 mg i.m. injection once every 28 days, +/- 2 days. RAD001 (everolimus) 10 mg per os daily.
Trial: NCT00368979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT03597555
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
Trial: NCT00232154
Drug: Zithromax&#153; (azithromycin) 500mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02734147
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01848002
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For 5 consecutive days, one daily dose of placebo was administered intravenously (IV) to two subjects in each dose group (10 or 25 U/kg).
Trial: NCT03303079
Drug: TEV-48125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEV-48125 will be subcutaneously administered once monthly for 3 months.
Trial: NCT03303079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be subcutaneously administered once monthly for 3 months.
Trial: NCT01596660
Drug: Bupivacaina 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaina 0.5% 20cc
Trial: NCT01596660
Drug: placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 cc of saline solution 0.9%, to infiltrate each side.
Trial: NCT03476577
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients are tested for their normal prescription ibuprofen medication
Trial: NCT01149538
Drug: Choline bitartrate
RxNorm normalized name: Choline Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
Trial: NCT00106561
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01566825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo(white 8 mm Lichtenstein®) at 9:30 pm, day 10, and at 1:30 am, day 11
Trial: NCT03052673
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms
Trial: NCT00728923
Drug: NPL-2003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (NPL-2003) daily for 12 weeks
Trial: NCT01906164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00138476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.
Trial: NCT01713127
Drug: remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01713127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01804335
Drug: CD5789 0.01% Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
Trial: NCT00565760
Drug: Q8003
RxNorm normalized name: POUCH,DRAINABLE,NEW IMAGE H#18003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT00565760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT03485456
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
Trial: NCT00640432
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75 mg oral capsule twice daily for 7 days
Trial: NCT00640432
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg oral capsule followed by 200 mg oral capsule with the evening meal (\>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days
Trial: NCT01765881
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administration of one sustained released pessary of 10 milligrams by intravaginal route
Trial: NCT01663987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a day (QD)
Trial: NCT02006654
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, matching placebo capsules, orally
Trial: NCT00890318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.
Trial: NCT02506140
Drug: Ticagrelor and Acetylsalicylic acid
RxNorm normalized name: codeine and acetylsalicylic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive a 180 mg loading dose of ticagrelor on the day of randomization, followed by 90 mg twice/day ticagrelor from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
Trial: NCT02487485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral dose
Trial: NCT01122953
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of Phenytoin 125 mg/5 ml suspension made by Laboratorios Pfizer, S.A. de C.V.
Trial: NCT03135795
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received intravenous sufentanil 0.5μg/kg for induction,and received PCA after surgery with sufentanil 1ug/ml using a controlled infusion pump, which was programmed to use a loading dose of 2ml, background infusion at 2m/h, PCA dose of 1ml, lockout time of 10min, and maximal dose of 12ml within 1 hour period.
Trial: NCT03135795
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received intavenous pump of remifentanil (0.1-0.2ug/kg/min) for maintenance.
Trial: NCT00945620
Drug: ropivicaine
RxNorm normalized name: Ropivicaine-Sufentanil Citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mL containing 300mg ropivicaine 1% with addition of 1:300,000 epinepherine
Trial: NCT00945620
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00849472
Drug: doxorubicin + cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.
Trial: NCT01761227
Drug: Fufangdanshen Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
Trial: NCT01761227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 3 tablets per time, 3 times per day for 24 weeks
Trial: NCT02506140
Drug: Clopidogrel and Acetylsalicylic acid
RxNorm normalized name: codeine and acetylsalicylic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive a 300 mg loading dose of clopidogrel on the day of randomization, followed by 75 mg once/day clopidogrel from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
Trial: NCT00309244
Drug: Technosphere® Insulin Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation, 15U/30U
Trial: NCT00902967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets of similar shape size and color given once a day at night time after meals
Trial: NCT03601052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection at site of second excisional wound
Trial: NCT01227395
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.~Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults.
Trial: NCT01990781
Drug: N: Normal saline (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline: 2ml
Trial: NCT00286455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
Trial: NCT01501513
Drug: PEG-3350 based bowel preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for oral administration prior to colonoscopy